Literature DB >> 24321469

Immunogammopathies and acquired vitelliform detachments: a report of four cases.

Irene M Rusu1, Sarah Mrejen2, Michael Engelbert3, Roberto Gallego-Pinazo4, Michael D Ober5, Mark W Johnson6, Anita Leys7, Lawrence A Yannuzzi8.   

Abstract

PURPOSE: To describe the nature and evolution of acquired macular detachments in patients with immunogammopathies and to propose a mechanism for their development.
DESIGN: Retrospective observational case series.
METHODS: Three patients with multiple myeloma and 1 with light chain deposition disease were diagnosed with vitelliform macular detachments based on clinical examination, fundus autofluorescence, fluorescein angiography, and optical coherence tomography. These patients were followed over time and their clinical examinations and imaging studies were compared and contrasted.
RESULTS: Three patients (5 eyes) with multiple myeloma and 1 patient (2 eyes) with light chain deposition disease presented with acquired macular yellowish subretinal deposits on funduscopic examination that corresponded to hyperautofluorescent lesions on fundus autofluorescence imaging and subretinal hyperreflective material on spectral-domain optical coherence tomography. One patient (2 eyes) had diffuse serous retinal detachments involving not only the macular region but also the midperiphery of the retina. These acquired macular vitelliform detachments were not associated with signs of hyperviscosity retinopathy in 5 eyes and resolved after successful treatment of the multiple myeloma in 6 eyes.
CONCLUSION: Patients with an immunogammopathy such as multiple myeloma or light chain deposition disease may develop serous elevations of the macula that we classify as acquired vitelliform detachments using multimodal imaging. Appropriate evaluation including serum protein electrophoresis and hematology consultation should be considered in the management of patients with acquired vitelliform detachments of uncertain etiology.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24321469     DOI: 10.1016/j.ajo.2013.11.020

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  6 in total

1.  Bevacizumab therapy and multimodal ultrawide-field imaging in immunogammopathy maculopathy secondary to Waldenström's macroglobulinemia.

Authors:  Lucy T Xu; Robert J Courtney; Justis P Ehlers
Journal:  Ophthalmic Surg Lasers Imaging Retina       Date:  2015-02       Impact factor: 1.300

2.  Nonantibestrophin Anti-RPE Antibodies in Paraneoplastic Exudative Polymorphous Vitelliform Maculopathy.

Authors:  Lauren A Dalvin; Adiv A Johnson; Jose S Pulido; Ranjit Dhaliwal; Alan D Marmorstein
Journal:  Transl Vis Sci Technol       Date:  2015-05-15       Impact factor: 3.283

3.  Serous macular detachment, yellow macular deposits, and prominent middle limiting membrane in multiple myeloma.

Authors:  Berna Dogan; Muhammet Kazim Erol; Devrim Toslak; Deniz Turgut Coban; Mehmet Bulut; Ayse Cengiz; Esin Sogutlu Sari
Journal:  Ther Clin Risk Manag       Date:  2015-04-30       Impact factor: 2.423

4.  Isolated posterior uveal effusion: expanding the spectrum of the uveal effusion syndrome.

Authors:  Scott E Pautler; David J Browning
Journal:  Clin Ophthalmol       Date:  2014-12-30

5.  Multimodal Imaging of Vitelliform Lesions in Multiple Myeloma: A Case Report.

Authors:  Abeir Baltmr; Andrew Lotery
Journal:  Case Rep Ophthalmol       Date:  2022-07-05

6.  Multimodal Chorioretinal Imaging in Erdheim-Chester Disease.

Authors:  Riccardo Sacconi; Corrado Campochiaro; Alessandro Rabiolo; Lorenzo Dagna; Giuseppe Querques; Alessandro Marchese; Alessandro Tomelleri; Livia Tomasso; Maria Vittoria Cicinelli; Lea Querques; Francesco Bandello
Journal:  Clin Ophthalmol       Date:  2020-02-28
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.